SGBV has assembled a team of individuals combining not only investor backgrounds but also entrepreneurial experiences in biotech companies.


Bernard Davitian, Vice President and Managing Director

Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction.

Bernard joined Sanofi in 2010 as Vice President, Deputy Global Head, Business Development Corporate Licenses and was promoted to Vice President and Managing Director of SGBV in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and COO & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO.

Bernard serves on the Board of Lysosomal Therapeutics and is a Board Observer for Yumanity Therapeutics and Unum Therapeutics. 

Bernard holds a MSc in Management (MBA equivalent) from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from Wharton Business School.



Jason P. Hafler, Senior Director of Investments and Principal

Jason joined Sanofi-Genzyme BioVentures in 2014 with a background in early stage biotech investing and transactions. Prior to SGBV, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason serves on the Board of NeuroVia Inc. and is a Board Observer for Navitor Pharmaceuticals. In addition, he is on the Board of Trustees at the Buckingham Browne and Nichols school and on the Board of Directors of The Magdalene College Foundation.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.


Ruchita Sinha, Senior Director of Investments

Ruchita joins us from GE Ventures, the corporate venture capital fund of GE. In this role, Ruchita invested in healthcare startups and built innovative partnership models that enable startups to scale and drive growth for GE. Ruchita served as a board observer for HeadSense Medical and Caremerge as well as managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. In addition, she managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and healthcare IT. Prior to joining GE, Ruchita was at Pfizer’s Corporate Strategy & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company.

Ruchita holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.